CSPC PHARMACEUT.GR. ADR4 - Asset Resilience Ratio
CSPC PHARMACEUT.GR. ADR4 (CVGU) has an Asset Resilience Ratio of 5.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CSPC PHARMACEUT.GR. ADR4's Asset Resilience Ratio has changed over time. See CSPC PHARMACEUT.GR. ADR4 (CVGU) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down CSPC PHARMACEUT.GR. ADR4's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is CSPC PHARMACEUT.GR. ADR4 worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.78 Billion | 5.94% |
| Total Liquid Assets | €2.78 Billion | 5.94% |
Asset Resilience Insights
- Limited Liquidity: CSPC PHARMACEUT.GR. ADR4 maintains only 5.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSPC PHARMACEUT.GR. ADR4 Industry Peers by Asset Resilience Ratio
Compare CSPC PHARMACEUT.GR. ADR4's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
|
Aurora Optoelectronics Co Ltd
SHG:600666 |
Drug Manufacturers - General | 5.89% |
|
NanJing Pharmaceutical Co Ltd
SHG:600713 |
Drug Manufacturers - General | 0.85% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for CSPC PHARMACEUT.GR. ADR4 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CSPC PHARMACEUT.GR. ADR4.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.94% | €2.78 Billion ≈ $3.25 Billion |
€46.70 Billion ≈ $54.59 Billion |
+2.63pp |
| 2024-12-31 | 3.32% | €1.47 Billion ≈ $1.72 Billion |
€44.39 Billion ≈ $51.90 Billion |
+0.99pp |
| 2023-12-31 | 2.33% | €1.08 Billion ≈ $1.26 Billion |
€46.28 Billion ≈ $54.11 Billion |
-6.23pp |
| 2022-12-31 | 8.56% | €3.57 Billion ≈ $4.18 Billion |
€41.77 Billion ≈ $48.83 Billion |
+4.40pp |
| 2021-12-31 | 4.15% | €1.44 Billion ≈ $1.69 Billion |
€34.74 Billion ≈ $40.62 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more